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and number of patient joints (0.649; P < 0.0001). CONCLUSIONS: The study con-
ﬁ rms the reliability and validity of a web administered version of the RADAI question-
naire in a US community sample. It is a useful measure to assess RA disease status for 
patient recruitment in interventional studies and for observational study designs.
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BACKGROUND: Patient-reported outcome (PRO) instruments such as the WOMAC 
Index of Osteoarthritis provide scores for outcomes that cannot be measured objec-
tively. However, such scores do not necessarily indicate patients’ perception of the 
relative importance of the domains and scales used in such instruments. OBJECTIVES: 
To obtain valid estimates of patient preferences for osteoarthritis domains and poten-
tial adverse outcomes. METHODS: Residents of the United Kingdom aged 45 years 
or older with a self-reported physician diagnosis of osteoarthritis (OA) completed a 
web-enabled conjoint-analysis or discrete-choice experiment survey. Patients evaluated 
10 pairs of hypothetical OA treatment-outcome proﬁ les. Each hypothetical OA treat-
ment was deﬁ ned by 4 beneﬁ t attributes derived from the WOMAC instrument 
(ambulatory pain, resting pain, stiffness, and daily activities) plus 3 adverse-event risk 
attributes (bleeding ulcer, stroke, and coronary infarction). Choice-model parameter 
estimates were obtained using random-parameters logit. RESULTS: A total of 294 
subjects provided usable data. Valid parameter estimates should indicate that better 
outcomes are preferred to worse outcomes. a main-effects choice model yielded cor-
rectly ordered, risk-level, preference-weight estimates for the 3 adverse-event attri-
butes, but disordered severity estimates for all 4 PRO attributes. Implausible 
combinations of ambulatory-pain and daily-activity levels may cause patients to focus 
on only one of the attributes. a model that excludes the daily-activity attribute and 
includes a dummy variable to account for implausible combinations yields correctly 
ordered preference-weight estimates. An improvement in ambulatory pain from 
25 mm to 0 mm on a 100 mm scale is approximately 1.7 times as important to 
patients as the same improvement in resting pain. CONCLUSIONS: Confounding 
among PRO domains can interfere with estimating valid preference weights and limit 
researchers’ ability to populate a model based on PRO outcomes with a full set of 
preference weights Controlling statistically for implausible outcome combinations 
successfully corrects the effect of the confounding and yields plausible trade-off values.
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OBJECTIVES: This study was designed to identify patient preferences for different 
aspects of severe ostheoporosis (SO) treatments in Spain. METHODS: Main attributes 
of SO treatments were determined from a review of the literature and consultations 
with nurses and patients. The discrete choice experiment included 3 attributes: type 
of drug administration, place of administration, plus a cost attribute in order to 
estimate willingness to pay (WTP) for improvements in attribute levels. a pilot study 
with 50 patients was carried forward to identify areas of misunderstanding. One 
hundred sixty-six patients with a diagnosis of SO were presented with pairs of hypo-
thetical treatment proﬁ les with varied levels of type of administration, place of admin-
istration and cost. Questions were also included to collect socio-demographic data. 
Data were analyzed using a random effects probit model. RESULTS: All attributes 
had the expected polarity and all were signiﬁ cant predictors of choice. Patients were 
willing to pay c183/month to have a subcutaneous injection once per day rather than 
an intravenous injection once per year. Patients were also willing to pay c121/month 
to have medical support when administering the drug treatment at home rather than 
being admitted several hours to a hospital for drug administration. CONCLUSIONS: 
Spanish SO patients have well-deﬁ ned preferences among treatment attributes and are 
willing to accept tradeoffs among attributes. Participants indicated that they are 
willing to accept self medication with medical support rather than being admitted to 
a hospital for several hours. The perspective of the patients should be taken into 
account when making treatment decisions.
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BACKGROUND: The premise of patients’ informed consent presupposes a preference 
structure over treatment related outcomes. OBJECTIVES: To assess patient prefer-
ences for treatment-related beneﬁ ts and risks associated with the NSAID use in the 
management of OA and examine differences in patient preferences across patient 
subgroups. METHODS: Eligible study participants, identiﬁ ed in a chronic disease 
panel in UK, were >44 yrs old with self-reported diagnosis of OA. Each patient was 
randomized to receive one of four blocks of choice questions, each block consisting 
of 10 choice tasks comparing different treatment proﬁ les of beneﬁ ts and risks consis-
tent with NSAID use. Treatment proﬁ les were deﬁ ned by four beneﬁ ts (ambulatory 
pain, resting pain, stiffness, difﬁ culty doing daily activities) and four medication-
related risks (bleeding ulcer, stroke, heart attack, hypertension), each varying across 
four clinically meaningful levels. Preference weights were estimated using mixed-effects 
logistic regression models and were standardized in a 0–10 (low-high) importance 
scale. Differences in patient preferences were assessed by stratifying age, hypertension 
diagnosis, and use of proton pump inhibitors (PPI). RESULTS: For the 294 study 
participants, average age was 59 years, 65% were female, 62% married, 56% diag-
nosed with OA > 4 years, 49% with hypertension, 76% on prescription OA medica-
tions and 36% on PPIs. Reductions in ambulatory pain (6.32; 95%CI:5.0–7.6) and 
difﬁ culty doing daily activities (6.32; 95%CI:5.0–7.6) were the most important beneﬁ t 
attributes followed by resting pain (2.80; 95%CI:1.8–3.8) and stiffness (2.65; 
95%CI:0.9–4.4). Incremental changes (3 percentage-point) in the risk of heart attack 
or stroke were assessed as the most important risk outcomes (10.00; 95%CI:8.2–11.8; 
and 8.90; 95%CI:7.3–10.5, respectively). a 2.5 percentage-point incremental change 
in one-year ulcer risk (3.61; 95%CI:2.6–4.6) and the risk of hypertension (3.02; 
95%CI:2.8–3.2) were valued less. The hypothesis of preferences homogeneity in 
patient subgroups was not rejected. CONCLUSIONS: Patients diagnosed with OA 
have well deﬁ ned preferences over NSAID-related beneﬁ ts and risks.
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OBJECTIVES: Rheumatoid Arthritis (RA) is a seriously debilitating disease affecting 
almost 0.7% of the adult population in Greece. Treatment options include, besides 
the conventional treatment with DMARDs, the use of newer biologic agents, which 
are available in the hospital (intravenous-iv) or the outpatient setting (subcutaneous-
sc). Patients are usually perceived to be averse to the use of iv treatments that may be 
essential to control their disease. We assessed quality of life, patients’ preferences, 
participation in decision making, when selecting the appropriate treatment for RA, 
and expected outcomes from the prescription medication. METHODS: Structured 
face-to-face and telephone interviews were conducted among 290 patients taking 
biologic agents. Patients were recruited from public hospitals (69.7%), ofﬁ ce based 
rheumatologists (22.8%) and private clinics (7.6%). Data were analyzed using SPSS 
v17.0. RESULTS: Median patient age was 55 years. 3/4 of the sample were women 
(74.8%). Approximately 1/3 of respondents reported they were not informed at all 
on adverse events (28.9%), treatment duration (31.4%) and prognosis (24.5%). For 
the greater part of the patients, the main source of information was their doctor. 
Treatment decisions were reached by the physician without patients’ involvement in 
most cases (70.6%). There was no statistically signiﬁ cant difference in patients’ satis-
faction between iv and sc treatments, whereas 62% of patients on sc treatment would 
be willing to switch to iv following their rheumatologist’s suggestion. Finally, “feeling 
better overall” was rated as the most important expected outcome by 63,2%, followed 
by reduced joint pain. Only 16% rated the long term remission of the disease as a 
very important outcome. CONCLUSIONS: An important proportion of patients with 
RA in Greece feel that they are not informed properly on treatment options, while 
their expectations may be understated. To improve outcomes, it is essential that 
rheumatologists overcome perceptions, inform and involve patients in the treatment 
decision.
